SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-093983
Filing Date
2024-08-08
Accepted
2024-08-08 16:13:36
Documents
66
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-20240630.htm   iXBRL 10-Q 2286118
2 EX-31.1 trvi-ex31_1.htm EX-31.1 14970
3 EX-31.2 trvi-ex31_2.htm EX-31.2 14944
4 EX-32.1 trvi-ex32_1.htm EX-32.1 9724
5 EX-32.2 trvi-ex32_2.htm EX-32.2 9684
  Complete submission text file 0000950170-24-093983.txt   8706227

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20240630.xsd EX-101.SCH 1164132
69 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20240630_htm.xml XML 1501493
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 241188490
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)